Research Papers:
The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis
Metrics: PDF 2089 views | HTML 2095 views | ?
Abstract
Wei Nie1, Xia Tao2, Hua Wei2, Wan-sheng Chen2, Bing Li1
1Department of Respiratory Medicine, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
2Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
Correspondence to:
Wan-sheng Chen, e-mail: [email protected]
Bing Li, e-mail: [email protected]
Keywords: Bcl-2-like protein 11, non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitor
Received: May 21, 2015 Accepted: July 15, 2015 Published: July 27, 2015
ABSTRACT
The prognostic value of Bcl-2-like protein 11 (BIM) deletion polymorphism for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment in non-small cell lung cancer (NSCLC) were reported. However, the results remained controversial. Thus, we did this systematic review and meta-analysis to address this issue. Databases including PubMed, Embase, and the Cochrane Register of Controlled Trials were searched to find relevant studies. The primary outcome was progression-free survival (PFS). Five retrospective cohort studies were included. All of the studies were conducted in Asian population (n = 951). The methodological quality of all included studies was high. Compared with BIM wild type, BIM deletion polymorphism was predictive of shorter PFS in NSCLC patients who were treated with EGFR-TKIs (adjusted HR = 2.38, 95% CI 1.66–2.41, P < 0.001). In conclusion, the BIM deletion polymorphism was associated with poor response in NSCLC patients who received EGFR-TKIs treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4678